Topical Drugs CDMO Market Size, Share & Industry Analysis, By Service Type (Product Development Services, Standalone Analytical and Testing Services, Clinical Manufacturing Services, Commercial Manufacturing Services, and Others), By Formulation (Semi-Solid Formulations [Creams, Ointments, Gel, and Others], Liquid Formulations, Solid Formulations, and Others), By Product Type (Prescription Drugs and OTC Drugs), By End User (Pharmaceutical Companies, Biopharmaceutical Companies, and Others), and Regional Forecast, 2026-2034

The global topical drugs CDMO market size was valued at USD 7.99 billion in 2025. The market is projected to grow from USD 8.60 billion in 2026 to USD 15.36 billion by 2034, exhibiting a CAGR of 7.5% during the forecast period.

Topical drugs CDMO refers to an outsourced partner that handles the research, formulation, testing, and development services of topical medications, including creams, gels, and others. The increasing prevalence of chronic diseases, expansion of novel topical applications, and growing outsourcing by pharmaceutical and biotechnological companies are resulting in a surging adoption rate of these services.

• According to 2026 data published by the American Academy of Dermatology Association (AADA), it was reported that about 50 million Americans are affected by acne in the U.S.

The expansion of Contract Development and Manufacturing Organizations (CDMOs) is further fueling the service adoption. The growing focus of key companies, including Douglas Limited and Piramal Pharma Solutions, on improving their service capabilities is further contributing to the demand for these services.

Topical Drugs CDMO Market Trends

Increasing Adoption of Digital Tools and Artificial Intelligence

The mounting utilization of digital technologies and artificial intelligence is emerging as a key trend in the global market. The process of topical drug development and manufacturing involves strict formulation and process variables, including ingredient compatibility, excipient selection, particle size, rheology, viscosity, mixing speed, and other prominent factors. CDMOs are increasingly deploying AI-enabled analytics, digital formulation platforms, and automated process-control systems to assess these variables more efficiently and enhance the reproducibility of ointments, gels, creams, foams, lotions, and other topical dosage forms.

Additionally, artificial intelligence and machine learning tools help CDMOs in formulation screening, stability prediction, experimental design, scale-up modelling, and the identification of relationships between processing conditions, raw-material attributes, and finished-product performance. This is resulting in the growing adoption of outsourcing services by pharmaceutical and biopharmaceutical companies.

• According to 2026 data published by the Drug Discovery News, the U.S. FDA cited more than 500 drug and biologic applications with AI components between 2016 and 2023.

Market Dynamics

Market Drivers

Download Free sample to learn more about this report.

Mounting Prevalence of Chronic Disorders to Drive Market Growth

The increasing prevalence of chronic diseases, including acne and eczema, is resulting in the growing demand for novel and effective drugs for various therapeutic areas. This further augments the outsourcing of drug development services, including product development services, analytical and testing services, to CDMOs by pharmaceutical and biopharmaceutical companies.

• According to 2026 data published by the National Psoriasis Foundation, more than 7.5 million adults are affected by psoriasis in the U.S.

In addition, the growing demand for generics and over-the-counter drugs and expansion of biotechnology and pharmaceutical models are augmenting the adoption of these services. The increasing focus of major companies on offering innovative services is further expected to push service adoption, propelling the global topical drugs CDMO market growth.

Market Restraints

High Investment in Specialized Manufacturing and Testing Infrastructure Could Limit Market Expansion

The significant investment required to establish the specialized manufacturing and testing infrastructure is anticipated to hamper the global market expansion. The topical drugs, including gels, creams, lotions, ointments, and foams, require dedicated compounding homogenizers, vessels, vacuum-processing systems, temperature-controlled mixing equipment, and specialized filling and packaging lines. Furthermore, advanced analytical and performance-testing laboratories require mass spectrometry, high-performance liquid chromatography, and other advanced systems for in vitro release testing and in vitro permeation testing. These aspects consequently increase the overall cost making it challenging for smaller CDMOs to adopt these systems, hampering market growth.

Market Opportunities

Expansion of Contract Development & Manufacturing Organizations to Create Opportunities

The expansion of topical drugs CDMOs across emerging countries presents lucrative opportunities for growth. There is an increasing establishment of contract development and manufacturing organizations, advanced laboratory networks, and research facilities across countries, including China and Brazil. Additionally, increasing healthcare expenditure, expanding pharma and biotech drug pipelines, and increasing government strategic initiatives to support innovation are contributing to the demand for pharmaceutical contract manufacturing services globally.

• According to 2023 data published by the World Bank Group, India’s spending on healthcare accounted for 3.34% of its GDP.

Market Challenges

Stringent and Evolving Regulatory Requirements to Create Challenges for Market Growth

Stringent and continuously evolving regulatory requirements represent a crucial challenge for companies operating in the global market. Topical drug products, especially ointments, creams, gels, lotions, and transdermal systems often require more extensive characterization due to relatively small differences in formulation composition, microstructure, and other factors. In addition, CDMOs serving multiple regions must comply with requirements from different regulatory bodies including the U.S. FDA, EMA, and other national regulators, while also updating development and manufacturing strategies. Changes in product-specific guidance further require additional studies, method redevelopment or reformulation, creating uncertainty for both sponsors and CDMOs, limiting the growth of the market.

SEGMENTATION ANALYSIS

By Service Type

Commercial Manufacturing Services Segment Dominated with Increasing Number of Prescriptions for Generic Medicines

Based on service type, the market is divided into product development services, standalone analytical and testing services, clinical manufacturing services, commercial manufacturing services, and others.

To know how our report can help streamline your business, Speak to Analyst

The commercial manufacturing services segment held the largest market share in 2025. This is due to the growing number of drug approvals, resulting in increasing demand for commercial manufacturing services among pharmaceutical and biopharmaceutical companies. The increasing prescription of generic drugs is further expected to contribute to segment growth.

• According to 2025 data published by the Association for Accessible Medicines (AAM), generic medicines represented about 90% of prescriptions filled in the U.S.

The standalone analytical and testing services segment is expected to grow at a CAGR of 11.0% over the forecast period.

By Formulation

Semi-Solid Formulations Segment Held Major Share owing to Increasing Adoption

Based on formulation, the market is segmented into semi-solid formulations, liquid formulations, solid formulations, and others.

The semi-solid formulations segment dominated the global market in 2025 with a share of 66.6%. The segment growth is owing to the rising benefits of semi-solid formulations, including localized and targeted drug delivery. This results in the rising outsourcing of drug development services for these products, contributing to the segmental growth. The semi-solid formulations segment is further divided into creams, ointments, gels, and others.

The solid formulations segment is set to flourish at a CAGR of 5.4% during the forecast period.

By Product Type

Increasing Prevalence of Chronic Conditions Led to the Dominance of the Prescription Drugs Segment

Based on product type, the market is bifurcated into prescription drugs and OTC drugs.

The prescription drugs segment dominated the global market in 2025. The segment growth is due to the increasing prevalence of chronic conditions and soaring demand for innovative drugs. These factors are driving a rise in the adoption of outsourcing services, contributing to segment growth.

• According to 2021 data published by ScienceDirect, about 7.3% of adults were affected by atopic dermatitis in the U.S.

The OTC drugs segment is poised to expand at a CAGR of 7.3% over the forecast period.

By End User

Pharmaceutical Companies Segment Recorded Dominant Share with Surge in R&D Expenditure

Based on end user, the market is subdivided into pharmaceutical companies, biopharmaceutical companies, and others.

The pharmaceutical companies segment dominated the market in 2025. The increasing demand for innovative drugs, rising outsourcing services, and surging R&D spending among pharmaceutical companies are some of the crucial factors contributing to the growth of the segment. The segment is set to hold a 40.7% share in 2026.

• According to 2022 data published by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the top 50 pharmaceutical companies alone are estimated to have spent a total of USD 167 billion in R&D initiatives.

In addition, the biopharmaceutical companies segment is projected to grow at a CAGR of 8.0% during the forecast period.

Topical Drugs CDMO Market Regional Outlook

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

Asia Pacific

To get more information on the regional analysis of this market, Download Free sample

The Asia Pacific market held the dominant share in 2024, valued at USD 2.50 billion, and also accounted for the leading share in 2025 with a value of USD 2.70 billion. The growing pharmaceutical outsourcing services and increasing development of topical drug formulation and semi-solid dosage forms are likely to contribute to the expansion of the market.

Japan Topical Drugs CDMO Market

In 2026, the Japan market is estimated to reach around USD 0.57 billion, accounting for roughly 6.6% of global revenues. This market is expected to grow due to an increase in the number of CDMOs.

China Topical Drugs CDMO Market

The China market is projected to be one of the largest markets worldwide, with 2026 revenues estimated at around USD 0.99 billion, representing roughly 11.5% of global sales.

India Topical Drugs CDMO Market

The India market size is estimated to touch around USD 0.47 billion in 2026, accounting for roughly 5.5% of global revenues.

North America

The North America market is estimated to reach USD 2.68 billion in 2026 and secure the position of the second-largest region in the market. The growing prevalence of chronic conditions, rising adoption of outsourcing services, increasing healthcare spending, and escalating adoption of digital tools are some of the key factors contributing to the growth of the segment.

• According to 2024 data published by the Centers for Medicare & Medicaid Services (CMS), healthcare expenditure stood at USD 5.3 trillion in the U.S.

U.S. Topical Drugs CDMO Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market can be analytically approximated at around USD 2.32 billion in 2026, accounting for roughly 27.0% of global sales.

Europe

The Europe market is projected to record a CAGR of 7.4% over the forecast period, which is the second highest among all regions. The regional market is anticipated to reach a valuation of USD 2.11 billion by 2026. The outsourcing of drug development services is likely to support the regional market growth.

U.K. Topical Drugs CDMO Market

The U.K. market is estimated to hit around USD 0.37 billion in 2026, representing roughly 4.3% of global revenue.

Germany Topical Drugs CDMO Market

The Germany market is projected to reach approximately USD 0.46 billion in 2026, equivalent to around 5.4% of global sales.

Latin America and Middle East & Africa

The Latin America and Middle East & Africa regional markets are expected to witness moderate growth during the forecast period. The Latin America market is set to reach a valuation of USD 0.51 billion in 2026. The increasing focus toward dermatology drug manufacturing, cream and ointment manufacturing, and gel formulation development are impelling the market growth in the region. The Middle East & Africa market is anticipated to grow with the escalating focus of key companies on GMP manufacturing services and topical pharmaceutical manufacturing services. In the Middle East & Africa, the GCC is set to reach a value of USD 0.08 billion in 2026.

South Africa Topical Drugs CDMO Market

The South Africa market is projected to reach around USD 0.06 billion in 2026, representing roughly 0.7% of global revenues.

Competitive Landscape

Key Industry Players

Increasing Focus of Key Players on Inorganic Growth Strategies to Support their Dominance

Douglas Limited and Piramal Pharma Solutions emerged as major companies in the market in 2025. A robust services portfolio and significant emphasis on inorganic strategies globally are key factors contributing to the dominance of these companies in the market. This growing focus on inorganic growth strategies is likely to strengthen their brand presence, further contributing to their topical drugs CDMO market share.

• In March 2025, Douglas Limited participated in a quality management program by the FDA designed to strengthen the global drug supply chain through evaluation of a company’s overall quality management systems beyond current Good Manufacturing Practice (cGMP) requirements.

Other key players, comprising Lubrizol and Aenova Holding GmbH, are  witnessing expansion, primarily due to their increasing focus on the provision of innovative services, including pharmaceutical formulation services.

List of Key Topical Drugs CDMO Companies Profiled

• MedPharm (U.K.)
• Lubrizol (U.S.)
• Douglas Limited (New Zealand)
• Piramal Pharma Solutions (India)
• Recipharm AB (Switzerland)
• Aenova Holding GmbH (Germany)
• CordenPharma (Switzerland)
• Delpharm (France)
• FAMAR (Greece)
• FAREVA (Luxembourg)

KEY INDUSTRY DEVELOPMENTS

• July 2026: Adhex Pharma announced a new toxicology laboratory, Labtec, at its Langenfeld site for handling new chemical entities, hormones, and highly potent APIs.
• March 2026: LGM Pharma, a provider of tailored API sourcing, contract analytical testing and CDMO services for the full drug product lifecycle, committed an additional USD 9.0 million to its facilities in Rosenberg, Texas, and Colorado Springs, Colorado.
• March 2026: CordenPharma acquired three drug product manufacturing facilities from Vifor Pharma to strengthen its presence in the market.
• July 2024: MedPharm, Ltd., merged with Tergus Pharma and created a contract development and manufacturing organization (CDMO), MedPharm, establishing an end-to-end CDMO with robust scientific, clinical trial manufacturing, and commercial production capabilities.
• August 2022: LTS LOHMANN Therapie-Systeme AG acquired Tapemark Inc., located in St. Paul, Minnesota, U.S. The move helped the company to strengthen its presence.

REPORT COVERAGE

The global topical drugs CDMO market report provides a detailed market analysis and focuses on key aspects such as leading companies and market segmentation, including service type, formulation, product type, and end user. Besides this, the global report offers insights into the factors driving market growth, market trends, and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth and advancement of the market over recent years.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation